Predictors of heterogeneity in the first-line treatment of patients with advanced/metastatic gastric cancer in the U.S.

被引：0
|
作者：
Thomas Abrams
Lisa M. Hess
Yajun Emily Zhu
William Schelman
Astra M. Liepa
Charles Fuchs
机构：
[1] Harvard Medical School,Dana
[2] Corporate Center,Farber Cancer Institute
[3] US Medical Affairs,Eli Lilly and Company, Global Patient Outcomes and Real World Evidence
[4] Yale Cancer Center,Eli Lilly and Company
来源：
Gastric Cancer | 2018年 / 21卷
关键词：
Population characteristics; Stomach neoplasms; Drug therapy; Antineoplastic agents;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：738 / 744
页数：6
相关论文
共 50 条
  • [1] Predictors of heterogeneity in the first-line treatment of patients with advanced/metastatic gastric cancer in the US
    Abrams, Thomas
    Hess, Lisa M.
    Zhu, Yajun Emily
    Schelman, William
    Liepa, Astra M.
    Fuchs, Charles
    GASTRIC CANCER, 2018, 21 (05) : 738 - 744
  • [2] Heterogeneity in the first-line treatment of patients with advanced or metastatic gastric cancer in the US
    Abrams, T.
    Hess, L.
    Zhu, Y.
    Schelman, W.
    Liepa, A.
    Fuchs, C.
    ANNALS OF ONCOLOGY, 2016, 27 : 115 - 115
  • [3] first-line cisplatin and irinotecan in advanced or metastatic gastric cancer
    Cheng, T. Y.
    Strava Correa, T.
    Andrade, A. Maria Guimaraes M. C.
    Queiroz Borges Muniz, D.
    Coelho Mesquita, M.
    Luiz Stelko Pereira, G.
    Pimenta Riechelmann, R.
    Marcelo Ghem Hoff, P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S439 - S439
  • [4] Pembrolizumab as a first-line treatment for advanced gastric cancer
    Chau, Ian
    LANCET ONCOLOGY, 2023, 24 (11): : 1158 - 1159
  • [5] FIRST-LINE TREATMENT IN HER2-POSITIVE ADVANCED OR METASTATIC GASTRIC CANCER
    Yamaguchi, K.
    Ooki, A.
    Yamada, T.
    Hara, H.
    Asayama, M.
    Tada, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 76 - 76
  • [6] Docetaxel and S-1 as a First-line Treatment in Patients with Advanced or Recurrent Gastric Cancer
    Tsutani, Yasuhiro
    Ohara, Masahiro
    Suzuki, Takahisa
    Minami, Kazuhito
    Miyahara, Eiji
    Kameda, Akira
    Noso, Yoshihiro
    ANTICANCER RESEARCH, 2009, 29 (07) : 2775 - 2779
  • [7] Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer
    Kruijtzer, CMF
    Boot, H
    Beijnen, JH
    Lochs, HL
    Parnis, FX
    Planting, AST
    Pelgrims, JMG
    Williams, R
    Mathôt, RAA
    Rosing, H
    Schot, ME
    van Tinteren, H
    Schellens, JHM
    ANNALS OF ONCOLOGY, 2003, 14 (02) : 197 - 204
  • [8] FIRST-LINE MAINTENANCE AND SECOND-LINE TREATMENT OF ADVANCED OR METASTATIC GASTRIC CANCER: A SYSTEMATIC REVIEW OF LITERATURE
    Singh, B.
    Attri, S.
    Kaur, G.
    Flynn, J.
    VALUE IN HEALTH, 2020, 23 : S421 - S421
  • [9] Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer
    Lan, Yan-qin
    Kong, Ling-jun
    Lin, Xiao-yan
    Xu, Qian
    Gao, Xin-yan
    Wu, Ri-ping
    Wang, Xin-li
    Zhong, Dong-ta
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (06) : 1007 - 1015
  • [10] Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer
    Luo, Hui-yan
    Xu, Rui-hua
    Wang, Feng
    Qiu, Miao-zhen
    Li, Yu-hong
    Li, Fang-hua
    Zhou, Zhi-wei
    Chen, Xiao-qin
    CHEMOTHERAPY, 2010, 56 (02) : 94 - 100
12345